During this time, Novartis also had many breakthroughs in the pharmaceuticals sector. One of the most significant advanced in cancer treatment in the first decade of the 21st century was Glivec ...

During this time, Novartis also had many breakthroughs in the pharmaceuticals sector. One of the most significant advanced in cancer treatment in the first decade of the 21st century was Glivec ...

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years Global drugmaker Novartis will lay off 427 employees who ...

In addition to IgAN, both Novartis and Travere are targeting other rare kidney diseases. Fabhalta a few days ago became the first FDA-approved agent for complement 3 glomerulopathy (C3G). Travere ...

Another wave of layoffs will impact Novartis‘ U.S. headquarters in New Jersey. In a filing with the state Department of Labor & Workforce Development, the East Hanover-based Swiss pharmaceutical ...

Entresto, approved in heart failure since 2015, has long been one of Novartis’ top growth drivers, bringing home $4.05 billion in U.S. sales in 2024. That said, a key combination patent on the ...

Novartis signed on to become the National Football League’s first-ever corporate pharmaceutical partner. As part of the new multi-year deal, the Swiss pharma giant said it aims to empower ...

North Carolina economic development officials have terminated an economic incentives agreement for Novartis Gene Therapies, which hasn’t met hiring targets tied to a package that promised up to ...

ZURICH, March 19 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday ...

TOKYO, March 17 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early ...